New Drug Delivery Approaches Critical to SiRNA Comeback

VANCOUVER, British Columbia – After the initial hype and some eye-watering investments, big pharma has abandoned the field of silent interfering RNA (siRNA) in the face of seemingly insuperable problems in getting those constructs to their targets.